Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma

Asher A. Chanan-Khan, Sagar Lonial, Donna Weber, Ivan M Borrello, Robin Foa, Andrzej Hellmann, Meletios Dimopoulos, Arlene S. Swern, Robert Knight

Research output: Contribution to journalArticle

Abstract

Two pivotal, phase III, randomised, placebocontrolled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma. This pooled, retrospective subanalysis of MM-009 and MM-010 analysed outcomes according to patient age. A total of 704 patients (390 aged

Original languageEnglish (US)
Pages (from-to)254-262
Number of pages9
JournalInternational Journal of Hematology
Volume96
Issue number2
DOIs
StatePublished - Aug 2012

Fingerprint

Multiple Myeloma
Dexamethasone
Survival
Placebos
lenalidomide
Therapeutics

Keywords

  • Elderly
  • Lenalidomide
  • Multiple myeloma
  • Refractory
  • Relapsed

ASJC Scopus subject areas

  • Hematology

Cite this

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. / Chanan-Khan, Asher A.; Lonial, Sagar; Weber, Donna; Borrello, Ivan M; Foa, Robin; Hellmann, Andrzej; Dimopoulos, Meletios; Swern, Arlene S.; Knight, Robert.

In: International Journal of Hematology, Vol. 96, No. 2, 08.2012, p. 254-262.

Research output: Contribution to journalArticle

Chanan-Khan, Asher A. ; Lonial, Sagar ; Weber, Donna ; Borrello, Ivan M ; Foa, Robin ; Hellmann, Andrzej ; Dimopoulos, Meletios ; Swern, Arlene S. ; Knight, Robert. / Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. In: International Journal of Hematology. 2012 ; Vol. 96, No. 2. pp. 254-262.
@article{906fc8b8261b4b21b7e7ebd471919e43,
title = "Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma",
abstract = "Two pivotal, phase III, randomised, placebocontrolled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma. This pooled, retrospective subanalysis of MM-009 and MM-010 analysed outcomes according to patient age. A total of 704 patients (390 aged",
keywords = "Elderly, Lenalidomide, Multiple myeloma, Refractory, Relapsed",
author = "Chanan-Khan, {Asher A.} and Sagar Lonial and Donna Weber and Borrello, {Ivan M} and Robin Foa and Andrzej Hellmann and Meletios Dimopoulos and Swern, {Arlene S.} and Robert Knight",
year = "2012",
month = "8",
doi = "10.1007/s12185-012-1125-7",
language = "English (US)",
volume = "96",
pages = "254--262",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma

AU - Chanan-Khan, Asher A.

AU - Lonial, Sagar

AU - Weber, Donna

AU - Borrello, Ivan M

AU - Foa, Robin

AU - Hellmann, Andrzej

AU - Dimopoulos, Meletios

AU - Swern, Arlene S.

AU - Knight, Robert

PY - 2012/8

Y1 - 2012/8

N2 - Two pivotal, phase III, randomised, placebocontrolled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma. This pooled, retrospective subanalysis of MM-009 and MM-010 analysed outcomes according to patient age. A total of 704 patients (390 aged

AB - Two pivotal, phase III, randomised, placebocontrolled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma. This pooled, retrospective subanalysis of MM-009 and MM-010 analysed outcomes according to patient age. A total of 704 patients (390 aged

KW - Elderly

KW - Lenalidomide

KW - Multiple myeloma

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=84866985895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866985895&partnerID=8YFLogxK

U2 - 10.1007/s12185-012-1125-7

DO - 10.1007/s12185-012-1125-7

M3 - Article

VL - 96

SP - 254

EP - 262

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -